Everything you need to win MicroTransponder — in one platform.
Who to reach, what to say, and why now on MicroTransponder — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on MicroTransponder — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
MicroTransponder Partners with Hospital Systems and Clinics to Enhance Vivistim Adoption for Chronic Stroke Recovery
Mar 16, 2025•about 1 year ago
Contract Type
partnership
Austin
Description
MicroTransponder, a leading stroke company, has announced a partnership with hospital systems and clinics to enhance the adoption of Vivistim for chronic stroke recovery. Vivistim is an FDA-approved intervention clinically proven to help chronic ischemic stroke survivors regain 2-3 times more upper extremity function than high-intensity stroke therapy alone.
Company Information
Company
MicroTransponder
Location
Austin, Texas, United States
About
The company plans to use the funds to commercialize the Vivistim® Paired VNS™ System and establish it as the recommended rehabilitation intervention for stroke survivors working to improve their quality of life through more hand and arm mobility. The company focuses on restoring independence and dignity for people suffering from neurological conditions that impair sensory and motor function. Vivistim is MicroTransponder's first FDA-approved use of its novel neuroplasticity-based medical device platform.
Predictive Intelligence
Strategic
ML-powered predictions for MicroTransponder's next move
Austin